ClinicalTrials.gg
CompletedNCT03976687Updated Sep 25, 2020

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients

A Phase 1 interventional study of EYP001a in NASH - Nonalcoholic Steatohepatitis and Healthy, sponsored by Enyo Pharma. Completed at 1 site in Australia. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Enyo Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2020, 6 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia — 8 open to participants now, 12 under way, 10 of them phase 3. Non-alcoholic Fatty Liver Disease · Australia.

Enrollment
54th of 54
16 · median 264
Started
2019
with 2 others
Phase 1
15 of 54
2 open now
Registered
19th of 54
by date

Among the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, this one is the 54th largest by enrollment, is one of 3 that started in 2019, is one of 15 in phase 1, and was the 19th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

8 of the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, or all of them as a file.
02

Study summary

This is a single centre, open label, randomized, 3 treatment arms, with and without food dosing, Phase 1b pharmacology study to assess the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Farnesoid X Receptor (FXR) agonist/modulator EYP001a in healthy volunteers and Nonalcoholic Steatohepatitis (NASH) patients.

Read the detailed description

In total 16 participants (4 healthy volunteers and 12 NASH patients) will be enrolled and randomly assigned to one of the 3 treatment arms:

  • Treatment Arm 1: Dose A once daily morning dose (n=4 NASH patients, n=4 healthy volunteers)
  • Treatment Arm 2: Dose B once daily morning dose (n=4 NASH patients)
  • Treatment Arm 3: Dose C twice daily - first morning dose and second dose 3 hours post first dose (n=4 NASH patients).

Subsequently, all the enrolled participants (both healthy volunteers and NASH patients) will be randomly assigned to one of the 2 parallel study Groups:

  • Group A (n=8, 2 healthy volunteers and 6 NASH patients): This group will include 2 NASH patients from Treatment Arms 1, 2 and 3 and 2 healthy volunteers from Treatment Arm 1. Participants in Group A will be dosed in a fasted state on Days 2, 3, 4 and 5 followed by dosing in fed state on Days 6, 7, 8 and 9.
  • Group B (n=8, 2 healthy volunteers and 6 NASH patients): This group will include 2 NASH patients from Treatment Arms 1, 2 and 3 and 2 healthy volunteers from Treatment Arm 1. Participants in Group B will be dosed in a fed state on Days 2, 3, 4 and 5 followed by dosing in fasted state on Days 6, 7, 8 and 9.

The maximum total engagement duration for eligible participants in this study is up to 76 days: 60 days screening, 1-day admission visit and 8 days dosing period (in-patient in clinical trial unit) and 7 days follow-up.

The participants who are eligible for enrolment will be admitted to the Clinical Trial Unit on Day 1. The participants will receive EYP001a at the study site by trained personnel per the schedule of dosing for the study from Day 2 to Day 9 in fed/fasted state depending upon the study group. Participants will be discharged on the morning (8:00 AM) of Day 10 after collection of last PK and PD blood samples. Participants will return to the Clinical Trial Unit on Day 16 for the follow-up visit.

03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis
  • Healthy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have given voluntary written ;
  2. Male/female participants aged 18 years to 75 years with a (BMI) ≥ 25 kg/m² and ≤ 45 kg/m² at screening.
  3. A female participant is eligible to participate in this study if:

    1. She is of non- (defined as females with a documented tubal ligation, bilateral oophorectomy or hysterectomy) or (defined as 12 months of spontaneous amenorrhea and follicle stimulating hormone level within the laboratory's reference range for postmenopausal females). A post-menopausal female receiving hormone replacement therapy (HRT) other than hormone replacement patches who is willing to discontinue hormone therapy 28 days before study drug dosing and agrees to remain off hormone replacement therapy for the duration of the study may be eligible for study participation. A post-menopausal female using Hormone Replacement patches who is willing to discontinue the patch 48 hours before Check in on Day -1 and until the completion of her End of Study visit is eligible for study participation.
    2. She is of childbearing potential and is non-pregnant or non-lactating and willing to use adequate from screening until 3 months after the End of Study visit. Adequate contraception is defined as a progesterone only intra uterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence in accordance with the lifestyle of the participant is acceptable.
    3. She is of childbearing potential and is non-pregnant or non-lactating and taking the combined oral contraceptive pill and willing to discontinue the combined oral contraceptive pill 7 days prior to check in on Day -1 and until the completion of her End of Study visit and use adequate contraception from the day of cessation. Adequate contraception is defined as a diaphragm or cervical cap together with a condom. Also, total abstinence in accordance with the lifestyle of the participant is acceptable.
  4. Have (ALT) >1.5 (ULN) during screening period.
  5. Fibroscan® Vibration-Controlled Transient Elastography (VTCE) liver stiffness (liver stiffness measure (LSM) for >8.5 kPa) and steatosis (Controlled Attenuation Parameter (CAP) ≥250 decibels per meter (dB/m)).
  6. Normal liver function at screening for alkaline phosphatase (ALP), Total (TBL), conjugated Bilirubin, , (INR).

Nota Bene: Criteria 4 and 5 do not apply to healthy volunteers.

Exclusion criteria

Exclusion Criteria:

  1. Employee of a contract research organization (CRO) participating in this study or the Sponsor.
  2. Patients with known non-NASH chronic liver disease (alcohol, , (HIV), virus (HBV), active virus (HCV)).
  3. Female with if no dual safe anti- method can be provided.
  4. Renal impairment (participants with an estimated (eGFR) computed from the Modification of Diet in Renal Disease (MDRD) formula of \< 60ml/min/1.73m² are excluded). Note: participants with mild renal impairment (eGFR >60 ml/min and ≤90 ml/min) are eligible.
  5. Has from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia.
  6. Has any known pre-existing medical or psychiatric condition that could interfere with the participant's ability to provide or participate in study conduct, or that may confound study findings.
  7. Has a history of clinically significant gastrointestinal (GI) disease, especially peptic ulcerations, GI bleeding, ulcerative colitis, Crohn's disease or Inflammatory Bowel Syndrome, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, or cardiovascular disease or any other condition which, in the opinion of the investigator, would jeopardize the safety of the participant or impact the validity of the study results.
  8. Has participated in any drug study within 60 days prior to the first drug administration in the current study.
  9. Has had major surgery within 30 days prior to the first drug administration.
  10. Concomitant use of not listed drugs after discussion with Sponsor not admitted.
  11. Has a history of relevant drug and/or food allergies
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    1: EYP001a Dose A

    Dose A once daily morning dose

    Drug: EYP001a

  • Experimental
    2: EYP001a Dose B

    Dose B once daily morning dose

    Drug: EYP001a

  • Experimental
    3: EYP001a Dose C

    Dose C twice daily - first dose morning dose and second dose 3 hours post first dose

    Drug: EYP001a

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of EYP001a

    Time frame: Day 2 through day 9

  2. Time to reach maximum concentration (Tmax) after EYP001a administration

    Time frame: Day 2 through day 9

  3. Area under the concentration-time curve (AUC) from time 0 to last measurable concentration (AUC0-10h and AUClast) of EYP001a

    Time frame: Day 2 through day 9

  4. Area under the concentration-time curve (AUC) and Maximum plasma concentration (Cmax) ratios

    Time frame: Day 2 through day 9

  5. Type and frequencies of Adverse events

    Time frame: Day 1 through day 16

Secondary outcomes

  1. Bile acid precursor : C4 (7αhydroxy-4-cholesten-3-one)

    pg/mL (picogram per milliliter). These will be measured in plasma samples using a validated method

    Time frame: Day 2 through day 9

  2. Bile acid precursor : Fibroblast growth factor 19 (FGF19)

    mg/mL (milligram per milliliter). These will be measured in plasma samples using a validated method

    Time frame: Day 2 through day 9

  3. Total Bile acids (secondary and primary)

    These will be measured in plasma samples using a validated method

    Time frame: Day 1 through day 9

07

Study locations

1 site
  • ENYO Pharma clinical site
    Randwick, New South Wales, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in May 2020, 11 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is close to that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2019
First posted
Jun 6, 2019
StartActual
Jun 11, 2019
Primary completionActual
May 25, 2020
CompletionActual
May 25, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03976687
Lead sponsor
Enyo Pharma
Responsible party
Sponsor
First posted
Jun 6, 2019
Start date
Jun 11, 2019
Primary completion
May 25, 2020
Completion
May 25, 2020
Last update
Sep 25, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EYP001A

Start the discussion